Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion. The centerpiece of the ...

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoimmune diseases Financing co-led by multiple ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to ...

Over the past decade, improved understanding of the physiological and molecular pathology of the cardiovascular system has ...